6-Mar-2026
PRNewswire (Mon, 2-Mar 5:31 PM ET)
Replimune Sets Stage for Key Investor Conferences Amid Novel Immunotherapy Progress
Market Chameleon (Mon, 2-Mar 3:51 AM ET)
Replimune to Present at Two Upcoming Investor Conferences
Globe Newswire (Mon, 2-Mar 8:00 AM ET)
Globe Newswire (Thu, 5-Feb 10:47 AM ET)
Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire (Tue, 3-Feb 8:00 AM ET)
Globe Newswire (Tue, 20-Jan 9:31 AM ET)
Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference
Globe Newswire (Thu, 18-Dec 8:00 AM ET)
Market Chameleon (Mon, 20-Oct 6:29 AM ET)
Market Chameleon (Mon, 20-Oct 3:32 AM ET)
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
Replimune Group trades on the NASDAQ stock market under the symbol REPL.
As of March 6, 2026, REPL stock price climbed to $8.07 with 2,671,169 million shares trading.
REPL has a beta of 0.54, meaning it tends to be less sensitive to market movements. REPL has a correlation of 0.00 to the broad based SPY ETF.
REPL has a market cap of $633.04 million. This is considered a Small Cap stock.
Last quarter Replimune Group reported $0 in Revenue and -$.77 earnings per share. This fell short of revenue expectation by $-3 million and exceeded earnings estimates by $.06.
In the last 3 years, REPL traded as high as $24.81 and as low as $2.68.
The top ETF exchange traded funds that REPL belongs to (by Net Assets): XBI, VTI, IWM, VXF, IWN.
REPL has underperformed the market in the last year with a price return of -34.3% while the SPY ETF gained +16.6%. REPL has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -23.9% and -5.6%, respectively, while the SPY returned -1.7% and -1.8%, respectively.
REPL support price is $6.68 and resistance is $7.41 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that REPL shares will trade within this expected range on the day.
